Cerebrospinal fluid nitrate levels in patients with Parkinson's disease.
It has been suggested that nitric oxide could be implicated in the neuronal degeneration of substantia nigra compacta in patients with Parkinson's disease. Recently, it has been reported decreased CSF nitrate levels (oxidation product that provides an indirect estimation of nitric oxide) in Parkinson's disease patients, assessed with a colorimetric method. We studied the CSF and plasma levels of nitrate with a kinetic cadmium-reduction method in 31 Parkinson's disease patients and 38 matched controls. The CSF and plasma nitrate levels were not correlated either in patient or in the control group, and they did not differ significantly between the two study groups. They were not influenced significantly by antiparkinsonian drugs in patients, although there was a trend for CSF nitrate levels to be higher in patients treated with levodopa or with dopamine agonists. CSF and plasma nitrate levels did not correlate with age at onset, duration, scores of the unified Parkinson's disease rating scales and Hoehn & Yahr staging in the patients group. These date suggest that CSF and plasma levels of nitrate are apparently unrelated with the risk for PD.
Molina
J A
JA
Department of Neurology, Hospital Doce de Octubre, Madrid, Spain.
Jiménez-Jiménez
F J
FJ
Navarro
J A
JA
Vargas
C
C
Gómez
P
P
Benito-León
J
J
Ortí-Pareja
M
M
Cisneros
E
E
Arenas
J
J
D001812:Blood-Brain Barrier / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D009566:Nitrates / Q000134:cerebrospinal fluid*; D009569:Nitric Oxide / Q000134:cerebrospinal fluid*; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000145:classification / Q000175:diagnosis*; D012016:Reference Values; D012307:Risk Factors
D009566:Nitrates; D009569:Nitric Oxide